The IPO market, which has been in a lull in recent weeks, is likely to pick up steam just in time for a year-end push.
The company has applied for listing its common shares on the Nasdaq under the ticker symbol "VIE."
Goldman Sachs, Morgan Stanley, Cowen and Guggenheim Securities are among the underwriters for the offering.
Viela is a clinical-stage biotech company developing treatments for autoimmune and severe inflammatory diseases. The company focuses on critical biological pathways shared across multiple indications.
The company's lead product candidate inebilizumab is a humanized monoclonal antibody targeting CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Inebilizumab is initially being developed as a first-line monotherapy treatment for neuromyelitis optica spectrum disorder, or NMOSD, a rare condition affecting the optic nerve, spinal cord and brain stem, invariably leading to irreversible blindness and paralysis.
Viela announced Tuesday the FDA's acceptance of its BLA for inebilizumab in NMOSD.
The rest of Viela's pipeline includes two additional clinical-stage and two pre-clinical product candidates, all focusing on a number of autoimmune diseases.
AstraZeneca has a 38.4% stake in the biotech, with agreements to supply clinical and commercial drug substances and products. Additionally, Viela's founding management team as well as a significant portion of its R&D staff are drawn from MedImmune, which AstraZeneca acquired in 2018.
Report: McAfee Could Fetch B Valuation In IPO
This Day In Market History: The Google IPO
See more from Benzinga
- Analysts: Ulta Beauty's Drastic Second-Half Guidance Cut A Blemish For Retailer
- AMD Desktop GPU Shipments Overtake Nvidia's For First Time In 5 Years
- Akari's 2-Day Rally: What You Need To Know
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.